GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Epigral Ltd

Epigral Q2 FY27 PAT Jumps 26% YoY to ₹ 64 Cr; Revenue up 28% to ₹ 752 Cr

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 02 Nov 2026, 01:59 PM IST  ·  BSE ID: eea0dbe4-5968-4351-bd83-405a7f364f79
View Original BSE Filing (PDF)
💡
In Simple Terms
Epigral's latest quarterly net profit rose 26% to ₹ 64 Crore, with sales up 28% to ₹ 752 Crore.
🤖 AI Summary
  • Epigral's Q2 FY27 PAT increased by 26% year-on-year to ₹ 64 Crore, up from ₹ 51 Crore in Q2 FY26.
  • Quarterly revenue for Q2 FY27 rose by 28% to ₹ 752 Crore, compared to ₹ 589 Crore in Q2 FY26.
  • Derivatives & Specialty business contributed 57% of total revenue in Q2 FY27, up from 50% in Q2 FY26.
  • H1 FY27 saw revenue rise 21% to ₹ 1,461 Crore and PAT increase 25% to ₹ 164 Crore.
  • CPVC and ECH expansions are in final stages, with commissioning expected within a quarter.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Q2 FY27 PAT
₹ 64 Cr
26%
Q2 FY27 Revenue
₹ 752 Cr
28%
H1 FY27 Revenue
₹ 1,461 Crore
21%
H1 FY27 PAT
₹ 164 Crore
25%
Q2 FY27 Derivatives & Specialty Revenue Contribution
57%
Q2 FY27 EBITDA
₹ 136 Crore
Q2 FY27 EBITDA Margin
18%
H1 FY27 Capex
₹ 88 Crore
🏢 How This Affects the Company
📈
Business Impact
The increased contribution of 57% from Derivatives & Specialty business indicates a shift towards higher-value products, potentially strengthening market positioning. Commissioning of CPVC and ECH expansions will increase production capacity.
💰
Financial Impact
Improved realisations and volume growth supported a 28% revenue increase. Elevated raw material costs compressed Q2 FY27 EBITDA margin to 18%, down from an unspecified prior quarter figure, but H1 FY27 EBITDA margin was maintained at 22%.
⚙️
Operational Impact
The ongoing expansion plans for CPVC and ECH plants are in their final stages, with trial runs underway, indicating increased operational capacity soon. ₹ 88 Crore capex in H1 FY27 supports growth projects.
⚠️
Risk Impact
Elevated raw material prices pose a risk to maintaining EBITDA margins, as observed in Q2 FY27. Geopolitical tensions and volatile price movements were noted as challenges during H1 FY27.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company reported Q2 FY27 PAT growth of 26% to ₹ 64 Crore and H1 FY27 PAT growth of 25% to ₹ 164 Crore, reflecting overall company performance.
🔍
Management Signal
Management is focused on executing expansion plans, strengthening the integrated manufacturing ecosystem, and increasing contribution from high-value specialty chemicals, with positive outlook for H2 FY27.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — monitor commissioning impact on revenue and margins.
Announcements on CPVC and ECH plant commissioning completion.
Updates on Epoxy Resin & Formulation and MPP projects progress and capex.
MEDIUM RISK Elevated raw material prices impacting EBITDA margins and geopolitical tensions affecting H1 FY27 are noted.
💡 Investor Takeaway
Epigral's Q2 FY27 Net Profit increased 26% year-on-year to ₹ 64 Crore, alongside a 28% revenue increase to ₹ 752 Crore. The Derivatives & Specialty business now accounts for 57% of revenue, confirming a strategic shift. CPVC and ECH expansions are nearing commissioning.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 PAT grew by 26% year-on-year to ₹ 64 Crore, demonstrating profit growth despite market challenges.
  • Revenue increased by 28% to ₹ 752 Crore in Q2 FY27, driven by volume growth and improved realisations.

⚠️ Concerns

  • Q2 FY27 EBITDA margin stood at 18%, muted by high cost of raw materials, lower than H1 FY27's 22%.
  • Geopolitical tensions, volatile price movements, and off-season for some products affected H1 FY27 performance.
📅 Company Track Record
Epigral previously reported Q1 FY27 standalone net profit of ₹ 99.18 Crore, a 25% increase, along with announcing ₹ 600 Crore capex for new plants. This Q2 FY27 filing confirms continued profit growth and provides updates on these expansion plans.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Epigral's net profit in Q2 FY27?
Epigral's net profit (PAT) in Q2 FY27 was ₹ 64 Crore, marking a 26% increase compared to ₹ 51 Crore in Q2 FY26.
What was Epigral's revenue in Q2 FY27?
Epigral reported a revenue of ₹ 752 Crore for Q2 FY27, which is a 28% increase from ₹ 589 Crore in Q2 FY26.
What was the contribution of Derivatives & Specialty business to Epigral's Q2 FY27 revenue?
The Derivatives & Specialty business contributed 57% of Epigral's total revenue in Q2 FY27, up from 50% in Q2 FY26.
What were Epigral's half-yearly (H1 FY27) financial highlights?
For H1 FY27, Epigral's revenue rose by 21% to ₹ 1,461 Crore, and PAT increased by 25% to ₹ 164 Crore.
What is the status of Epigral's expansion projects?
Epigral's CPVC and ECH expansions are in their final stages with trial runs underway, expected to commission in a quarter's time. Epoxy Resin & Formulation and MPP projects are progressing as planned.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.